Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ ADXS opened at $0.03 on Tuesday. The stock has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.81. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $1.49. The company has a 50-day moving average of $0.05 and a 200 day moving average of $0.11.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.